based in seattle wa epigenomics was founded in berlin germany in 1998 around the same time orca biosciences was founded in seattle wa the companies merged in 2000 and have focused on applying dna methylation based biomarkers to address medical needs epigenomics became a publicly traded company with its listing on the frankfurt exchange in 2004 the company maintains a work force in berlin as well as in seattle epigenomics is focused on developing and marketing molecular diagnostics for oncology the company has discovered dna methylation based biomarkers for a number of oncology related indications has developed enabling technologies for the analysis of methylation in blood and other body fluids and is bringing medically important products to the market key contributions to biomarker science based on dna methylation include sept9 measurement in blood for detection of colon cancer shox2 measurement in lung fluid to aid in diagnosis of lung cancer pitx2 measurement in prostate tissue as a prognosis factor for prostate cancer the company continues to focus on discovering and validating dna methylation based biomarkers and developing the technology to make dna methylation testing a routine practice in the clinical laboratory where possible the results of these efforts are shared